
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a clinical-stage biotechnology company with a positive outlook as evidenced by strong financials including $106.9 million in cash and equivalents as of March 2026, and a net loss of $127.5 million for 1Q26. With their product candidates SZN-8141, SZN-413, and SZN-8143 targeting Wnt pathway mediation in a variety of retinal diseases, Surrozen has the potential to provide important innovations and address unmet needs in the retinal disease space. Risks to their investment thesis and target price include failure to commercialize their developmental candidates and secure capital resources, but their advancements in the retinal therapeutic space and potential for earlier therapeutic use make them a strong contender in the market.
Bears say
Surrozen is a clinical-stage biotech company with a focus on developing novel therapeutics in severe eye diseases and other organs, using the Wnt signaling pathway. However, the company is still in the early stages of development and faces risks such as failure to achieve peak commercial revenue estimates and secure sufficient funding. Additionally, the success of their lead candidate SZN-8141 may be impacted by unexpected toxicities or competing studies. Based on these factors, the future success and growth of Surrozen is uncertain, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares